Ocular delivery of triamcinolone acetonide phosphate and related compounds

Abstract

The present invention provides systems and methods for ocularly delivering a triamcinolone acetonide agent to a subject. In one aspect, for example, a method is provided for treating or preventing an ocular condition in a subject for which triamcinolone acetonide is effective. Such a method may include ocularly administering a triamcinolone acetonide agent to the subject in order to treat or prevent the condition. Although any administration technique is contemplated, in some aspects a triamcinolone acetonide agent may be delivered to eye tissue via ocular iontophoresis.

1 . A method for treating or preventing an ocular condition in a subject for which triamcinolone acetonide is effective, comprising: 
 administering a triamcinolone acetonide agent to an eye of the subject in order to treat or prevent the condition.    
   
   
       2 . The method of  claim 1 , wherein the triamcinolone agent is a member selected from the group consisting of triamcinolone acetonide, triamcinolone acetonide phosphate, and combinations thereof.  
   
   
       3 . The method of  claim 2 , wherein the triamcinolone agent is triamcinolone acetonide phosphate.  
   
   
       4 . The method of  claim 2 , wherein the triamcinolone agent is triamcinolone acetonide.  
   
   
       5 . The method of  claim 4 , wherein the triamcinolone acetonide is coadministered with a solubilizing agent.  
   
   
       6 . The method of  claim 1 , wherein administering the triamcinolone acetonide agent further includes ocular iontophoretic administration.  
   
   
       7 . The method of  claim 1 , wherein the condition is a member selected from the group consisting of macular edema, age related macular degeneration, anterior, intermediate, and posterior uveitis, HSV retinitis, diabetic retinopathy, bacterial, fungal, or viral endophthalmitis, eye cancers, glioblastomas, glaucoma, glaucomatous degradation of the optic nerve, and combinations thereof.  
   
   
       8 . The method of  claim 1 , further comprising co-administering a vasoconstricting agent with the triamcinolone acetonide agent.  
   
   
       9 . The method of  claim 8 , wherein the vasoconstricting agent is a member selected from the group consisting of naphazoline, tetrahydrozoline, phenylethylamine, epinephrine, norepinephrine, dopamine, dobutamine, colterol, ethylnorepinephrine, isoproterenol, isoetharine, metaproterenol, terbutaline, metearaminol, phenylephrine, tyramine, hydroxyamphetamine, ritrodrine, prenalterol, methoxyamine, oxymethazoline, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, methentermine, phentermine, fenfluramine, propylhexedrine, diethylpropion, phenmetrazine, phendimetrazine, and combinations thereof.  
   
   
       10 . The method of  claim 9 , wherein the vasoconstricting agent is oxymethazoline.  
   
   
       11 . A system for treating or preventing a condition in a subject for which triamcinolone acetonide is effective, comprising: 
 an ocular device having a drug reservoir; and    a triamcinolone agent disposed within the drug reservoir.    
   
   
       12 . The system of  claim 11 , wherein the triamcinolone agent is a member selected from the group consisting of triamcinolone acetonide, triamcinolone acetonide phosphate, and combinations thereof.  
   
   
       13 . The system of  claim 12 , wherein the triamcinolone agent is triamcinolone acetonide phosphate.  
   
   
       14 . The system of  claim 11 , wherein the ocular device is an iontophoretic ocular device.  
   
   
       15 . The system of  claim 14 , further comprising a pernselective material functionally coupled to the drug reservoir.  
   
   
       16 . The system of  claim 11 , wherein the ocular device further includes an enhancer reservoir configured to contain an enhancing agent.  
   
   
       17 . The system of  claim 16 , wherein the enhancer reservoir contains a vasoconstricting agent.  
   
   
       18 . The system of  claim 17 , wherein the vasoconstricting agent is a member selected from the group consisting of naphazoline, tetrahydrozoline, phenylethylamine, epinephrine, norepinephrine, dopamine, dobutamine, colterol, ethylnorepinephrine, isoproterenol, isoetharine, metaproterenol, terbutaline, metearaminol, phenylephrine, tyramine, hydroxyamphetamine, ritrodrine, prenalterol, methoxyamine, oxymethazoline, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, methentermine, phentermine, fenfluramine, propylhexedrine, diethylpropion, phenmetrazine, phendimetrazine, and combinations thereof.  
   
   
       19 . The system of  claim 18 , wherein the vasoconstricting agent is oxymethazoline.